Dow AgroSciences Divests European Dithane Business to Indofil Industries Ltd.
5.3.2012 06:00:26 CET | Business Wire | Press release
Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), has divested its European Dithane® fungicide business to Indofil Industries Ltd. of Mumbai, India.
The agreement includes only Dithane® products sold in Europe and does not include other parts of the Dow AgroSciences’ Dithane business.
Indofil, part of India’s K.K. Modi Group, has purchased the rights and associated trademarks of Dithane® only in Europe, exclusive rights to use the patented NT technology and related trademarks in Europe, Dithane® registrations and data to support these, and the customer contracts which can be assigned.
“Dow AgroSciences remains committed to the Dithane® business in other parts of the world where we have production assets and are better able to compete over time,” says David Hindes, Global Fungicide Business Leader. “This divestment will allow us to focus our European investment on new novel chemistries in the future.”
“This is an exciting time for Indofil Industries in Europe, consolidating Indofil’s position in the European mancozeb market segment and making it a leading player,” says K.K. Modi, Group Chairman, K.K. Modi Group.
Indofil was the manufacturer and distributor of Dithane® in India for 40 years under Rohm and Haas. “Indofil is excited to welcome the Dithane product back in its portfolio, and is committed to growing the Dithane® market across Europe, through active collaboration with all partners,” says R.K. Malhotra, CEO, Indofil Industries Limited.
The companies are working together to ensure a seamless transition and minimal impact to customers, distributors, and dealers.
Financial terms of the agreement were not disclosed.
About Dow AgroSciences
Dow AgroSciences, based in
Indianapolis, Indiana, USA, develops leading-edge crop protection and
plant biotechnology solutions to meet the challenges of the growing
world. Dow AgroSciences is a wholly owned subsidiary of The Dow Chemical
Company and had annual global sales of $5.7 billion in 2011. Learn more
at www.dowagro.com
.
Follow Dow AgroSciences on Facebook
and
YouTube
or
subscribe to our News
Release RSS Feed
.
About Indofil Industries Limited
Indofil Industries Limited,
established more than four decades ago, headquartered in Mumbai, is a
research-led, fully integrated agri-business company. Since 2007,
Indofil has grown at an annual rate of 27%. With a state-of-the-art
manufacturing set-up, an experienced R&D team, and a strong domestic and
international distribution network, Indofil manufactures and sells crop
protection products and specialty chemicals products across the globe.
Indofil was the manufacturer and distributor of Dithane in India, for 40
years, under Rohm and Haas. Today, it leads the Indian Mancozeb market
and exports Mancozeb formulations to more than 50 countries. Indofil was
recognized as the “Best Company from an Emerging Region” at the AGROW
awards, London, in 2010.
For more information visit: www.indofilcc.com
Contact:
Dow AgroSciences
Robyn Heine, 317-337-4807
rheine@dow.com
or
Indofil
Industries Limited
Shekhar Shetty, +91 22 66637403
sdshetty-icc@modi.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom